Grifols SA
MAD:GRF

Watchlist Manager
Grifols SA Logo
Grifols SA
MAD:GRF
Watchlist
Price: 9.202 EUR -0.71% Market Closed
Market Cap: 6.2B EUR
Have any thoughts about
Grifols SA?
Write Note
Section:
 

Relative Value

The Relative Value of one GRF stock under the Base Case scenario is 29.439 EUR. Compared to the current market price of 9.202 EUR, Grifols SA is Undervalued by 69%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GRF Relative Value
Base Case
29.439 EUR
Undervaluation 69%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.9
P/S
P/S
Price to Sales
0.9
vs History
90
vs Industry
87
Median 3Y
1.2
Median 5Y
2.2
Industry
7.6
Forward
0.9
More Details
43.4
P/E
P/E
Price to Earnings
43.4
vs History
19
vs Industry
6
Median 3Y
31.1
Median 5Y
26.1
Industry
22.1
Forward
13.8
More Details
11.5
P/OCF
P/OCF
Price to OCF
11.5
vs History
87
vs Industry
2
Median 3Y
19.4
Median 5Y
18.2
Industry
21.9
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7
Median 5Y
4
Industry
23.4
More Details
1.2
P/B
P/B
Price to Book Value
1.2
vs History
82
vs Industry
59
Median 3Y
1.3
Median 5Y
2
Industry
2.5
More Details
2
EV/S
EV/S
Enterprise Value to Sales
2
vs History
88
vs Industry
67
Median 3Y
2.3
Median 5Y
3.3
Industry
7.5
Forward
2
More Details
5.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.2
vs History
85
vs Industry
50
Median 3Y
5.8
Median 5Y
7.7
Industry
9.3
More Details
9.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.9
vs History
92
vs Industry
9
Median 3Y
12.9
Median 5Y
14
Industry
4.2
Forward
7.9
More Details
14.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
14.3
vs History
92
vs Industry
7
Median 3Y
18.2
Median 5Y
18.5
Industry
4
Forward
11.3
More Details
26.2
EV/OCF
EV/OCF
Enterprise Value to OCF
26.2
vs History
55
vs Industry
1
Median 3Y
29.5
Median 5Y
27.2
Industry
5.9
More Details
67.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
67.2
vs History
15
vs Industry
Median 3Y
-126.9
Median 5Y
32.2
Industry
3.9
More Details
0.7
EV/IC
EV/IC
Enterprise Value to IC
0.7
vs History
87
vs Industry
62
Median 3Y
0.8
Median 5Y
1
Industry
4.5
More Details

Multiples Across Competitors

GRF Competitors Multiples
Grifols SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Grifols SA
MAD:GRF
6.2B EUR 0.9 43.4 9.9 14.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 142 781.8 -181 287 -220 140.1 -217 628.1
US
Abbvie Inc
NYSE:ABBV
315.2B USD 5.7 62 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
141.9B USD 4.4 33.5 16.1 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD 4.1 923.6 10.3 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD 9.8 -217.7 21.5 22.6
US
Epizyme Inc
F:EPE
94.1B EUR 1 847 -471.3 -513.2 -499.6
AU
CSL Ltd
ASX:CSL
135.7B AUD 5.7 32.1 19.9 24.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 5.7 16.9 15.4 17.1
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.6 -52.9
NL
argenx SE
XBRU:ARGX
36B EUR 19.3 -135.2 -109.2 -79.6
P/S Multiple
Revenue Growth P/S to Growth
ES
Grifols SA
MAD:GRF
Average P/S: 3 467 700.2
0.9
24%
0
FR
Pharnext SCA
OTC:PNEXF
38 142 781.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
34%
0.3
US
E
Epizyme Inc
F:EPE
1 847
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.3
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
ES
Grifols SA
MAD:GRF
Average P/E: 185.3
43.4
1 304%
0
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 287 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
923.6
77%
12
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -217.7
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.3 N/A N/A
AU
CSL Ltd
ASX:CSL
32.1
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
Grifols SA
MAD:GRF
Average EV/EBITDA: 15.5
9.9
95%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 140.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16.1
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.5
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.2 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
Grifols SA
MAD:GRF
Average EV/EBIT: 20.4
14.3
133%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 628.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -499.6 N/A N/A
AU
CSL Ltd
ASX:CSL
24.8
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.6 N/A N/A

See Also

Summary
GRF intrinsic value, competitors valuation, and company profile.
DCF Valuation
GRF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GRF stock valuation using valuation multiples.
Wall Street Estimates
GRF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GRF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.